Literature DB >> 21848174

Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO.

Ozlem Bilen1, Laura Loftis, Jun Teruya.   

Abstract

We aim to present the case of a 5-week-old girl with severe respiratory failure placed on veno-venous extracorporeal membrane oxygenation (ECMO) that was then switched to veno-arterial ECMO. She required up to 60 units/kg/hr of heparin to keep her heparin level within the target range at .3-.7 units/mL. During the ECMO course, substantial thrombus formation was observed within the venous site of the ECMO cannula, which led to two circuit changes on ECMO day 9 and day 20. On ECMO day 15, she was noticed to have purpuric lesions on her chest and her right hand with no obvious arterial or venous clot detected by Doppler ultrasound. She was also noted to have remarkable hemolysis as the plasma free hemoglobin levels were substantially elevated up to 700 mg/dL. She was noted to have continuous oozing from the catheter insertion sites despite adequate underlying coagulation status. Her subsequent platelet function analysis, the thromboelastography, and thromboelastography platelet mapping suggested substantial platelet dysfunction. Her von Willebrand panel revealed absence of high molecular weight multimers. Further coagulation workup was prompted which revealed heterozygosity for factor V Leiden. The patient developed severe pulmonary hemorrhages and ECMO was discontinued on day 40.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848174      PMCID: PMC4680025     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  13 in total

1.  Acquired von Willebrand syndrome and Wilms tumor: not always benign.

Authors:  Patricia A Baxter; Jed G Nuchtern; Robert P Guillerman; Donald H Mahoney; Jun Teruya; Murali Chintagumpala; Donald L Yee
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

Review 2.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Authors:  Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

3.  Influence of platelet factor 4 on the neutralization of heparin by protamine.

Authors:  J N Shanberge; T M Quattrociocchi-Longe
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

4.  Inherited Thrombophilia due to Factor V Leiden Mutation.

Authors: 
Journal:  Mol Diagn       Date:  1998-03

5.  Evaluation of heparin assay for coagulation management in newborns undergoing ECMO.

Authors:  Wassia A Khaja; Ozlem Bilen; Ralf B Lukner; Rachel Edwards; Jun Teruya
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

6.  Prevalence of factor V Leiden in children with thrombo-embolism.

Authors:  I Aschka; V Aumann; F Bergmann; U Budde; W Eberl; S Eckhof-Donovan; S Krey; U Nowak-Göttl; R Schobess; A H Sutor; J Wendisch; R Schneppenheim
Journal:  Eur J Pediatr       Date:  1996-12       Impact factor: 3.183

7.  Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome.

Authors:  T Agorastos; A Karavida; A Lambropoulos; T Constantinidis; S Tzitzimikas; S Chrisafi; H Saravelos; D Vavilis; A Kotsis; J Bontis
Journal:  J Matern Fetal Neonatal Med       Date:  2002-10

8.  Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.

Authors:  Francesca Del Balzo; Alberto Spalice; Martino Ruggieri; Filippo Greco; Enrico Properzi; Paola Iannetti
Journal:  Acta Paediatr       Date:  2009-04-30       Impact factor: 2.299

9.  Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Authors:  José Villagra; Sruti Shiva; Lori A Hunter; Roberto F Machado; Mark T Gladwin; Gregory J Kato
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

10.  Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine.

Authors:  R Britt McILwain; Joseph G Timpa; Ashish R Kurundkar; David W Holt; David R Kelly; Yolanda E Hartman; Mary Lauren Neel; Rajendra K Karnatak; Robert L Schelonka; G M Anantharamaiah; Cheryl R Killingsworth; Akhil Maheshwari
Journal:  Lab Invest       Date:  2009-11-09       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.